Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

摘要: Abstract Purpose To evaluate efficacy, complications and preprocedural risk factors for percutaneous image-guided core needle biopsy of malignant tumours genomic tumour analysis. Materials and methods Procedural data biopsies performed at a single centre the MOSCATO-01 clinical trial were prospectively recorded between December 2011 March 2016. Data assessed included patient demographics, characteristics, procedural outcomes complications. Results A total 877 under computed tomography (38.4%) or ultrasound guidance (61.6%) in liver (n = 363), lungs (n = 229), lymph nodes (n = 138), bones (n = 15) other miscellaneous sites (n = 124). Each harvested mean 4.4 samples [1–15], with adequate yield analysis 95.3% cases. complications occurred 89 cases (10.1%), minor grade I 59 (66.3%); II 16 (18%) and III 14 (15.7%). No IV no procedure-related death occurred. The most common pneumothorax (51/89, 57.3%), haemorrhage (24/89, 27%) and pain (8/89, 8.9%). Predictive by univariate biopsied organ (lung vs other), sample number, prone position, lesion size, depth approach. By multivariate analysis, only pulmonary was significant factor (odds ratio = 27.23 [4.93–242.76], p  Conclusion Percutaneous cancer patients provides an effective method to obtain molecular screening samples, overall low complication rate. Lung mass present higher complication, although are manageable minimally invasive techniques without prolonged sequelae.